Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
The DOI matches its Crossref record; 74 of the 75 references it cites were found in a registry or an index.
Abstract
Maintaining research and development (R&D) productivity at a sustainable level is one of the main challenges currently facing the pharmaceutical industry. In this article, we discuss the results of a comprehensive longitudinal review of AstraZeneca's small-molecule drug projects from 2005 to 2010. The analysis allowed us to establish a framework based on the five most important technical determinants of project success and pipeline quality, which we describe as the five 'R's: the right target, the right patient, the right tissue, the right safety and the right commercial potential. A sixth factor - the right culture - is also crucial in encouraging effective decision-making based on these technical determinants. AstraZeneca is currently applying this framework to guide its R&D teams, and although it is too early to demonstrate whether this has improved the company's R&D productivity, we present our data and analysis here in the hope that it may assist the industry overall in addressing this key challenge.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is accumulating evidence that the success of candidate drugs is greatly enhanced if the drug target is independently confirmed by human genetic data.16, 17”
From Early Neurological Change After Ischemic Stroke Is Associated With 90-Day Outcome (2021) · cites this paper as [16]
In the citing paper
“Currently, techniques like structural magnetic resonance imaging (MRI), and molecular imaging of deposited Aβ and tau proteins using positron emission tomography (PET), are highly accurate in detecting the presence of pathophysiological and neuropathological changes of AD and are used in the drug development [10, 11].”
From Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease (2020) · cites this paper as [10]
In the citing paper
“In the past, other medical fields tried to address similar problems by increasing the volume of trials.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [106]
In the citing paper
“In reality, research and development costs increased while the number of drugs approved remained static106,107.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [106]
In the citing paper
“Early initiation of PK/PD assessment facilitates understanding of the biology by validating and confirming target engagement.50”
From Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development (2018) · cites this paper as [50]
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 4×
“Although clinical validation was not confirmed in the Phase IIa studies, retrospective analysis suggested that AZD1981 showed limited efficacy in an atopic/allergic asthma population selected by a positive skin prick test.”
BackgroundInfluentialInhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Genomic responses in mouse models poorly mimic human inflammatory diseases
Seok, J., Warren, H. S., Cuenca, A. G., Mindrinos, M. N., Baker, H. V., Xu, W., Richards, D. R., McDonald-Smith, G. P., Gao, H., Hennessy, L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222878110 · Cited by 3,005 · cited 1×
“29 (13) Dose limited by compound characteristics or tissue exposure not established”
BackgroundPavord, I. D., Korn, S., Howarth, P., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H., & Chanez, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60988-x · Cited by 2,221
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981 · cited 1×
“11 (5) Evidence from previous phase not robust enough”
BackgroundLeckie, M. J., Brinke, A. T., Khan, J., Diamant, Z., O'Connor, B. J., Walls, C. M., Mathur, A. K., Cowley, H. C., Chung, K. F., Djukanovic, R., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03496-6 · Cited by 1,814
Lebrikizumab Treatment in Adults with Asthma
Corren, J., Lemanske, R. F., Hanania, N. A., Korenblat, P. E., Parsey, M. V., Arron, J. R., Harris, J. M., Scheerens, H., Wu, L. C., Su, Z., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106469 · Cited by 1,514
Research works printed but not linked: 3
- Herper, M. The truly staggering cost of inventing new drugs. Forbes [online] , (10 Feb 2012).
- Redfern, W. et al. Impact and frequency of different toxicities throughout the pharmaceutical life cycle. The Toxicologist 114, 231 (2010).
- Quirk, M. et al. Abstract P-09-045. Effects of low-trapping NMDA channel blocker AZD6765 on gamma-band EEG and psychotomimetic liability: a comparison to ketamine in freely behaving rats. Int. J. Neuropsychopharmacol. 15 (Suppl. S1), 153 (2012).
Cited by
Items 501–600 of 1,000
Investigational prostaglandin D2receptor antagonists for airway inflammation
Santini, G., Mores, N., Malerba, M., Mondino, C., Macis, G., & Montuschi, P. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1175434 · Cited by 22
“had limited, if any, efficacy on functional outcome measures in patients with mild-to-moderate and moderate-to-severe asthma, respectively.[74] Clinical development of setipiprant (2-(2-(1-naphthoyl)-8fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid 28 (ACT-129968) (Actelion), a selective, potent (IC50 =…”
BackgroundMethodImplications of topological imbalance for representation learning on biomedical knowledge graphs
Bonner, S., Kirik, U., Engkvist, O., Tang, J., & Barrett, I. P. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac279 · Cited by 36
“Drug discovery and development is a highly complex, lengthy and multi-disciplinary endeav-our [11], associated with high costs and attrition, particularly due to efficacy failure [29] which is in turn underpinned by the hypothesis of which drug target(s) is thought to play a key role in a given…”
BackgroundTherapeutic potential of the Proprotein Convertase Subtilisin/Kexin family in vascular disease
Suur, B. E., Chemaly, M., Liljeqvist, M. L., Djordjevic, D., Stenemo, M., Bergman, O., Karlöf, E., Lengquist, M., Odeberg, J., Hurt‐Camejo, E., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.988561 · Cited by 22
“potential therapeutic targets were highlighted in a study from 2014, where the establishment of a link between the target and the disease via genetic causal association coupled to the proof-ofmechanism, was shown to be crucial in early stages of drug development to ensure successful clinical translation (Cook et al.,…”
BackgroundMethodInfluentialCritical Roles of METTL3 in Translation Regulation of Cancer
Meng, W., Han, X., Mei, P., Chen, J., Wang, Y., Zhao, R., & Liao, Y. (2023) · Biomolecules · doi:10.3390/biom13020243 · Cited by 23
“Since the determinants of successful clinical application of small molecule inhibitors include confirmation of the compound-mechanism hypothesis, compound-target action and pharmacodynamic activity [96], if the likelihood of successful drug development is to be maximized, a high standard of screening for inhibitors ta…”
BackgroundBrott, D., Furlong, S. T., Adler, S. H., Hainer, J. W., Arani, R. B., Pinches, M., Rossing, P. R., & Chaturvedi, N. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s78792 · Cited by 22
Kell, D. B. (2015) · Perspectives in Science · doi:10.1016/j.pisc.2015.06.004 · Cited by 23
One Drug for Multiple Targets: A Computational Perspective
Méndez‐Lucio, O., Naveja, J. J., Vite‐Caritino, H., Prieto-Martínez, F. D., & Medina‐Franco, J. L. (2017) · Journal of the Mexican Chemical Society · doi:10.29356/jmcs.v60i3.100 · Cited by 36
Parmentier, C., Hendriks, D. F. G., Heyd, B., Bachellier, P., Ingelman‐Sundberg, M., & Richert, L. (2018) · Toxicology Letters · doi:10.1016/j.toxlet.2018.06.1069 · Cited by 22
Rudmann, D. G. (2019) · Toxicologic Pathology · doi:10.1177/0192623318809065 · Cited by 22
Defining subpopulations of differential drug response to reveal novel target populations
Keshava, N., Toh, T. S., Yuan, H., Yang, B., Menden, M. P., & Wang, D. Y. Q. (2019) · npj Systems Biology and Applications · doi:10.1038/s41540-019-0113-4 · Cited by 24
Wallis, R., Gharanei, M., & Maddock, H. L. (2015) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2015.05.009 · Cited by 22
Imam, S. Z., He, Z., Cuevas, E., Rosas-Hernández, H., Lantz, S. M., Sarkar, S., Raymick, J. B., Robinson, B. L., Hanig, J. P., Herr, D. W., et al. (2017) · Experimental Biology and Medicine · doi:10.1177/1535370217739859 · Cited by 22
Innovating cancer drug discovery with refined phenotypic screens
Wang, Z., Hulíková, A., & Swietach, P. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.06.001 · Cited by 25
Complex in vitro models positioned for impact to drug testing in pharma: a review
Kang, S., Chen, E. C., Cifuentes, H., Co, J. Y., Cole, G., Graham, J. C., Hsia, I., Kiyota, T., Klein, J. A., Kroll, K. T., et al. (2024) · Biofabrication · doi:10.1088/1758-5090/ad6933 · Cited by 25
“Cardiotoxicity is one of the leading causes of drug attrition [20], with the risk of drug-induced fatal arrhythmias such as Torsade de pointes driving development of initial in vitro cardiac models—first from 1.”
Quantitative systems toxicology: modelling to mechanistically understand and predict drug safety
Goldring, C. E., Russomanno, G., Pin, C., Trairatphisan, P., Beattie, K. A., Fisher, C., Piñero, J., Brennan, R., Clausznitzer, D., Copple, I. M., et al. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01308-z · Cited by 28
Genomics of drug target prioritization for complex diseases
Chen, R. K., Duffy, Á., & Do, R. (2025) · Nature Reviews Genetics · doi:10.1038/s41576-025-00904-4 · Cited by 30
“The limited data on decision-making within pharmaceutical companies 4,5,9,31 suggest they are considering genetic evidence at earlier stages of the drug development pipeline 8 .”
Aldi, S., Matic, L. P., Hamm, G. R., van Keulen, D., Tempel, D., Holmstrøm, K., Szwajda, A., Nielsen, B. S., Emilsson, V., Ait-Belkacem, R., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.05.003 · Cited by 21
“13,14 LPA is an amphipatic phospholipid that can interact with cell membranes by its detergent properties but also by its association to LPA-speci fi c receptors (LPARs 1 – 6).”
Evaluation of biomarkers for in vitro prediction of drug-induced nephrotoxicity in RPTEC/TERT1 cells
Qiu, X., Miao, Y., Geng, X., Zhou, X., & Li, B. (2020) · Toxicology Research · doi:10.1093/toxres/tfaa005 · Cited by 21
In vitro differentiation modifies the neurotoxic response of SH-SY5Y cells
Conto, V. D., Cheung, V., Maubon, G., Souguir, Z., Maubon, N., Vandenhaute, E., & Bérézowski, V. (2021) · Toxicology in Vitro · doi:10.1016/j.tiv.2021.105235 · Cited by 26
Insight into Thermodynamic and Kinetic Profiles in Small-Molecule Optimization
Liu, W., Jiang, J., Lin, Y., You, Q., & Wang, L. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00682 · Cited by 22
Neuroimaging Biomarkers for Drug Discovery and Development in Schizophrenia
Preller, K. H., Scholpp, J., Wunder, A., & Rosenbrock, H. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.01.009 · Cited by 27
“The availability of biomarkers is a critical factor for the success of drug development (13), and neuroimaging is in a prime position to deliver insights into the pathophysiology of the living brain.”
Prior, H. M., Bottomley, A., Champéroux, P., Cordes, J. S., Delpy, E., Dybdal, N. O., Edmunds, N., Engwall, M., Foley, M., Hoffmann, M., et al. (2016) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2016.03.004 · Cited by 22
In vitro assessment of chemotherapy-induced neuronal toxicity
Snyder, C. A., Yu, L., Ngo, T., Sheinson, D. M., Zhu, Y., Tseng, M., Misner, D., & Staflin, K. (2018) · Toxicology in Vitro · doi:10.1016/j.tiv.2018.02.004 · Cited by 22
Computational Toxicology and Drug Discovery
Hasselgren, C., & Myatt, G. J. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7899-1_11 · Cited by 25
Hwang, S.-H., Lee, S., Park, J. Y., Jeon, J. S., Cho, Y., & Kim, S. (2021) · Micromachines · doi:10.3390/mi12020215 · Cited by 24
“examined why some drug development programs at AstraZeneca failed and found that insufficient efficacy data led to failure rates of 57%–88% in phase II clinical trials [60].”
BackgroundProgression-seeking bias and rational optimism in research and development
Lendrem, D. W., Lendrem, C., Peck, R., Senn, S. J., Day, S. J., & Isaacs, J. D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4320-c1 · Cited by 22
Integrating Biological Networks for Drug Target Prediction and Prioritization
Ji, X., Freudenberg, J., & Agarwal, P. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8955-3_12 · Cited by 20
Mina, S. G., Alaybeyoglu, B., Murphy, W. L., Thomson, J. A., Stokes, C. L., & Cirit, M. (2019) · Frontiers in Big Data · doi:10.3389/fdata.2019.00023 · Cited by 22
“Given that central nervous system (CNS) toxicity is a leading cause of toxicity-related clinical trial failures (Cook et al., 2014; Walker et al., 2018), the predictive capabilities of current preclinical toxicity testing methods remain inadequate.”
BackgroundAdvances in 3D Organoid Models for Stem Cell-Based Cardiac Regeneration
Martin, M., Gähwiler, E. K. N., Generali, M., Hoerstrup, S. P., & Emmert, M. Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065188 · Cited by 21
“Furthermore, because the majority of pre-clinical research is conducted using 2D cell culture and animal models, which do not always resemble the human system, translation of potential therapies usually fails in Phase 1 clinical trials [81].”
BackgroundRockley, K. L., Roberts, R. A., Jennings, H., Jones, K. L., Davis, M., Lévesque, P., & Morton, M. J. (2023) · Toxicological Sciences · doi:10.1093/toxsci/kfad087 · Cited by 24
Renal Safety Pharmacology in Drug Discovery and Development
Benjamin, A., da Costa, A. N., Delaunois, A. G., Rosseels, M.-L. A., & Valentin, J. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-662-46943-9_13 · Cited by 20
In vivo phenotypic screening: clinical proof of concept for a drug repositioning approach
Ciallella, J. R., & Reaume, A. G. (2017) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2017.04.001 · Cited by 24
Doornbos, M. L. J., der Linden, I. V., Vereyken, L., Tresadern, G., IJzerman, A. P., Lavreysen, H., & Heitman, L. H. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.03.026 · Cited by 22
Systematically Prioritizing Candidates in Genome-Based Drug Repurposing
Challa, A. P., Lavieri, R. R., Lewis, J. T., Zaleski, N. M., Shirey-Rice, J. K., Harris, P. A., Aronoff, D. M., & Pulley, J. M. (2019) · Assay and Drug Development Technologies · doi:10.1089/adt.2019.950 · Cited by 20
Innovative approaches in CNS drug discovery
Charvériat, M., Lafon, V., Mouthon, F., & Zimmer, L. (2020) · Therapies · doi:10.1016/j.therap.2020.12.006 · Cited by 21
Metwally, M., Bayoumi, A., Khan, A., Adams, L. A., Aller, R., García‐Monzón, C., Arias, M., Bugianesi, E., Miele, L., Alisi, A., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103521 · Cited by 22
“Several analyses of pharmaceutical pipelines have suggested that drugs for targets in which a genetic link to disease is evident has nearly double the likelihood of successful clinical development with improved cost-effectiveness, compared to those not having such a link [7,8].”
BackgroundA Framework for Managing Innovation
Kavadias, S., & Hutchison‐Krupat, J. (2020) · doi:10.1287/educ.2020.0219 · Cited by 23
Suhara, T., Chaki, S., Kimura, H., Furusawa, M., Matsumoto, M., Ogura, H., Negishi, T., Saijo, T., Higuchi, M., Omura, T., et al. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw111 · Cited by 21
“Empirical evidence supports this notion: a retrospective analysis of AstraZeneca’s R&D projects from 2005 to 2010 revealed that projects with high confidence in patient selection demonstrated a greater likelihood of success in Phase IIb (Cook et al., 2014).”
BackgroundNorden, D. M., Navia, C. T., Sullivan, J. T., & Doranz, B. J. (2024) · mAbs · doi:10.1080/19420862.2024.2393785 · Cited by 21
“32 However, most of their pipeline at the time focused on small molecules, and a similar study of biologics has not yet been published.”
Yang, H., Stebbeds, W., Francis, J., Pointon, A., Obrezanova, O., Beattie, K. A., Clements, P., Harvey, J., Smith, G. F., & Bender, A. (2022) · Stem Cell Reports · doi:10.1016/j.stemcr.2022.01.009 · Cited by 21
“Cardiovascular toxicity often results in delays in drug discovery and development and additional clinical monitoring (Cook et al., 2014).”
BackgroundLorefice, L., Pitzalis, M., Murgia, F., Fenu, G., Atzori, L., & Cocco, E. E. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1076421 · Cited by 22
“This is supported by retrospective analyses (Cook et al., 2014; Nelson et al., 2015) showing that drugs developed to target molecules identified by genetic associations are more likely to pass efficacy testing.”
MethodImplementation of digital health technology in clinical trials: the 6R framework
Duran, C., Bonam, M., Björk, E., Hughes, R., Ghiorghiu, S., Massacesi, C., Campbell, A., Hutchison, E. R., Pangalos, M. N., & Galbraith, S. M. (2023) · Nature Medicine · doi:10.1038/s41591-023-02489-z · Cited by 19
Self-citationBias translation: The final frontier?
Kenakin, T. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16335 · Cited by 26
In silicotools used for compound selection during target-based drug discovery and development
Caldwell, G. W. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1043885 · Cited by 25
Modeling timelines for translational science in cancer; the impact of technological maturation
McNamee, L. M., & Ledley, F. D. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174538 · Cited by 21
“The publication record will also include research related to the metrics included in Lipinski’s “rule of 5,”[75] considered the gold standard for successful, small molecule drugs, as well as the knowledge base represented by Astra-Zeneca’s “5 R’s”[76] or analogous rubrics used in other organizations as predictors of d…”
MethodCiccimaro, E., Zhu, Y., Ostanin, D. V., Suchard, S. J., MacGuire, J. G., Xiao, Q., Dongré, A. R., Chimalakonda, A., Olah, T. V., & Shipkova, P. A. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.7b00688 · Cited by 19
Applications of Computers in Pharmaceutical Product Formulation
Deb, P. K., Al-Attraqchi, O. H. A., Al-Qattan, M. N. M., Mailavaram, R. P., & Tekade, R. K. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814421-3.00019-1 · Cited by 22
Pathway analysis of GWAS loci identifies novel drug targets and repurposing opportunities
Jhamb, D., Magid-Slav, M., Hurle, M. R., & Agarwal, P. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.03.024 · Cited by 19
Kidney Safety Assessment: Current Practices in Drug Development
Troth, S. P., Simutis, F., Friedman, G. S., Todd, S., & Sistare, F. D. (2019) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2018.12.002 · Cited by 20
Microengineered systems with iPSC-derived cardiac and hepatic cells to evaluate drug adverse effects
Dame, K., & Ribeiro, A. J. S. (2020) · Experimental Biology and Medicine · doi:10.1177/1535370220959598 · Cited by 24
“Reichel and Lienau(143) reviewed how preclinical pharmacokinetic data enhance the success rate of drug discovery and referenced practical examples from the industry.(144,145) A key concept in pharmacokinetic studies is drug clearance.”
BackgroundCardiovascular microphysiological systems (CVMPS) for safety studies – a pharma perspective
Pointon, A., Maher, J. M., Davis, M., Baker, T. K., Cichocki, J. A., Ramsden, D., Hale, C. M., Kolaja, K. L., Lévesque, P., Sura, R., et al. (2021) · Lab on a Chip · doi:10.1039/d0lc01040e · Cited by 22
Addressing the Right Targets in Oncology: Challenges and Alternative Approaches
Stock, J. K., Jones, N. P., Hammonds, T. R., Roffey, J., & Dillon, C. (2015) · SLAS DISCOVERY · doi:10.1177/1087057114564349 · Cited by 21
“A good example of this is illustrated by a recent publication from AstraZeneca describing some of the lessons learned following a comprehensive longitudinal review of their small-molecule programs from 2005 to 2010.(14) This led to the implementation of an operating model described as the “5 R’s.”
MethodChicken Soup in the Time of COVID
Rennard, S. I., Kalil, A. C., & Casaburi, R. H. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.04.044 · Cited by 19
“The vast majority of promising agents with supporting evidence fail to become medicines for a variety of reasons, including toxicity and lack of efficacy.(2) Although common knowledge among clinical researchers, it is often a surprise to many in the general public.”
Giblin, K. A., Basili, D., Afzal, A. M., Rosenbrier-Ribeiro, L., Greene, N., Barrett, I., Hughes, S. J., & Bender, A. (2021) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.0c00311 · Cited by 18
The grand challenge of discovering new cardiovascular drugs
Hong, C. C. (2022) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2022.1027401 · Cited by 21
“Given the extraordinary costs and risks of developing NMEs, the pharmaceutical and biotech industries are investing in genomics to improve target selection and decrease the risk of failure from lack of efficacy (Cook et al., 2014) or adverse effects (Nguyen et al.”
BackgroundBamps, D., Blockeel, A. J., Dreesen, E., Marynissen, H., Laenen, J., Hecken, A. V., Wilke, A. V., Shahabi, S., Johnson, K. W., Collins, E. C., et al. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3024 · Cited by 21
Attrition in the Pharmaceutical Industry: Reasons, Implications, and Pathways Forward
Alex, A., Smith, D. A., & Harris, C. (2015) · Cited by 18
Akhmetov, I., & Bubnov, R. V. (2017) · The EPMA Journal · doi:10.1007/s13167-017-0078-6 · Cited by 19
“On the other hand, in many countries, to link reimbursement to cost-effectiveness via clear dialogue between the commercial and scientific groups become a common practice ensuring a “right culture” for promoting truth-seeking rather than progression-seeking behavior [50] for differentiated and reimbursable medicine, i…”
BackgroundFrom Reproducibility to Translation in Neurodegenerative Disease
Zeiss, C. J. (2017) · ILAR Journal · doi:10.1093/ilar/ilx006 · Cited by 21
You-on-a-chip’ for precision medicine
Low, L. A., & Tagle, D. A. (2018) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2018.1456333 · Cited by 18
Connecting genetics and gene expression data for target prioritisation and drug repositioning
Ferrero, E., & Agarwal, P. (2018) · BioData Mining · doi:10.1186/s13040-018-0171-y · Cited by 21
“Selecting the right targets is a key decision early in the drug discovery pipeline [13]: a large proportion of the efficacy failures in clinical programmes are due to lack of a clear link between the therapeutic target and the disease under investigation [14].”
BackgroundModeling the value of predictive affinity scoring in preclinical drug discovery
Abel, R., Manas, E. S., Friesner, R. A., Farid, R., & Wang, L. (2018) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2018.09.002 · Cited by 19
Receptor Occupancy Measurement of Anti-PD-1 Antibody Drugs in Support of Clinical Trials
Fu, J., Wang, F., Dong, L., Xing, M.-J., Cheng, X., Wei, S., Xu, J.-Z., Han, M., Dong, K., & Song, H. (2019) · Bioanalysis · doi:10.4155/bio-2019-0090 · Cited by 19
Brown, D. G., Smith, G. F., & Wobst, H. J. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01625 · Cited by 20
Self-citationAbi‐Gerges, N., Miller, P. E., & Ghetti, A. (2019) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201021666191210142023 · Cited by 19
Andronis, C., Silva, J. P., Lekka, E., Virvilis, V., Carmo, H., Bampali, K., Ernst, M. C., Hu, Y., Loryan, I., Richard, J., et al. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02788-1 · Cited by 22
An integrative network-based approach for drug target indication expansion
Han, Y., Wang, C., Klinger, K. W., Rajpal, D. K., & Zhu, C. (2021) · PLoS ONE · doi:10.1371/journal.pone.0253614 · Cited by 21
“Additionally, human genetic evidence on a drug target has been reported to play an increasingly important role on achieving a successful clinical trial [14].”
BackgroundLamba, D., & Pesaresi, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095072 · Cited by 17
“TcAChE was isolated and purified as previously described [66], except for the affinity chromatography ligand, mono-(aminocaproyl)-p-aminophenyltrimethylammonium.”
MethodMaynard, J., Emmas, S.-A., Blé, F.-X., Barjat, H., Lawrie, E., Hancox, U. J., Oakes, D., Polanska, U. M., & Barry, S. T. (2016) · EJNMMI Research · doi:10.1186/s13550-016-0220-9 · Cited by 18
“To address this limitation, we have considered whether non-invasive techniques can enable a patient’s tumour(s) to be screened for PI3K isoform dependency to guide effective selection of patients for therapy [15].”
Yu, P. Y., Gardner, H. L., Roberts, R., Cam, H., Hariharan, S., Ren, L., LeBlanc, A. K., Xiao, H., Lin, J., Guttridge, D. C., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0181885 · Cited by 17
“One of the key technical factors contributing to project failures is lack of efficacy secondary to working on the wrong target for the disease of interest [38].”
BackgroundMurck, H., LAUGHREN, T. P., Lamers, F., Picard, R. W., Walther, S., GOFF, D. C., & Sainati, S. M. (2015) · Europe PMC (PubMed Central) · doi:10.7892/boris.69085 · Cited by 19
“Almost a decade later, the same issues of patient selection and target engagement were dominant themes in a review of the failures in drug development at Astra Zeneca between 2005 and 2010.(2) One area, which received considerable interest in the meantime for the solution of these problems, is the exploration of indiv…”
BackgroundAssessment of a 3D neural spheroid model to detect pharmaceutical-induced neurotoxicity
Wang, Q. L., Cohen, J. D., Yukawa, T., Estrella, H., Leonard, C., Nunes, J., Choi, C., Lewis, L., Baker, K. S., Kuga, K., et al. (2022) · ALTEX · doi:10.14573/altex.2112221 · Cited by 24
“…qin.wang@takeda.com) neurological liability span a wide variety of areas, not only found in drugs intended for central nervous system (CNS) indications, but also frequently reported in the cardiovascular and gastrointestinal therapeutic areas (Cook et al., 2014; Walker et al., 2018).”
BackgroundEckernäs, E., Timmermann, C., Carhart-Harris, R. L., Röshammar, D., & Ashton, M. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12933 · Cited by 17
Sin, D. D. (2023) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2023.0005 · Cited by 19
Combining Human and Rodent Genetics to Identify New Analgesics
Latrémolière, A., & Costigan, M. (2017) · Neuroscience Bulletin · doi:10.1007/s12264-017-0152-z · Cited by 18
Lundgren, H., Martinsson, K., Cederbrant, K., Jirholt, J., Mucs, D., Madeyski-Bengtson, K., Havarinasab, S., & Hultman, P. A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0184744 · Cited by 17
Nanoformulated Paclitaxel and AZD9291 Synergistically Eradicate non-small-cell Lung Cancers In Vivo
Wang, X.-S., Zhang, L., Li, X., Kong, D.-J., Hu, X.-C., Ding, X.-Z., Yang, J.-Q., Zhao, M.-Q., He, Y., Lam, K. S., et al. (2018) · Nanomedicine · doi:10.2217/nnm-2017-0355 · Cited by 17
Jansen, J. E., Gaffney, E. A., Wagg, J., & Coles, M. C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01283 · Cited by 20
Petersson, C., Papasouliotis, O., Lecomte, M., Badolo, L., & Dolgos, H. (2019) · Xenobiotica · doi:10.1080/00498254.2019.1625084 · Cited by 19
“These 2 parameters (CL and VDss) are therefore central in candidate drug selection process and are a part of the framework for the selection of the starting dose in human (Cook et al., 2014; Dolgos et al., 2016).”
BackgroundBatista-Filho, J., Falcão, M. A. P., Maleski, A. L. A., Soares, A. B. S., Balan-Lima, L., Disner, G. R., Lima, C., & Lopes‐Ferreira, M. (2020) · Toxicology Reports · doi:10.1016/j.toxrep.2020.12.004 · Cited by 20
Random Forest Model Prediction of Compound Oral Exposure in the Mouse
Mughal, H., Wang, H., Zimmerman, M., Paradis, M. D., & Freundlich, J. S. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00197 · Cited by 17
The Challenges of Precision Oncology Drug Development and Implementation
Hollingsworth, S. J., & Biankin, A. V. (2015) · Public Health Genomics · doi:10.1159/000441557 · Cited by 22
Acri, J. B., Cross, A. J., & Skolnick, P. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4501-9 · Cited by 18
“This study is conducted in female smokers because preclinical toxicology findings precluded a clinical trial of this length in both sexes (Cook et al. 2014).”
BackgroundSeda, M., Geerlings, M. J., Lim, P., Jeyabalan, J., Cichon, A.-C., Scambler, P. J., Beales, P. L., Hernández-Hernández, V., Stoker, A. W., & Jenkins, D. (2018) · Molecular Syndromology · doi:10.1159/000491567 · Cited by 18
“This is important because AstraZeneca reported that data linking a biological target to disease in human subjects and samples were available for 73–82% of the projects that remained active in Phase II, whereas 57–60% of the projects failed on the basis of efficacy where human data was not previously available [Cook et…”
BackgroundGadaleta, D., de Lomana, M. G., Serrano‐Candelas, E., Ortega-Vallbona, R., Gozalbes, R., Roncaglioni, A., & Benfenati, E. (2024) · Journal of Cheminformatics · doi:10.1186/s13321-024-00917-x · Cited by 25
“These organ-specific adversities are of primary concern in drug safety assessment, with organ toxicity identified as a major contributor to preclinical safety attrition [12].”
When Science is Not Enough: A Framework Towards More Customer-Focused Drug Development
Oraiopoulos, N., & Dunlop, W. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0567-y · Cited by 17
“The existence of this progression-driven behavior is also highlighted in an extensive longitudinal study of AstraZeneca’s small-molecule pipeline that examined the root causes behind project failures [15].”
BackgroundKlima, S., Brüll, M., Spreng, A., Suciu, I., Falt, T., Schwamborn, J. C., Waldmann, T., Karreman, C., & Leist, M. (2021) · Archives of Toxicology · doi:10.1007/s00204-021-03024-0 · Cited by 17
“We focused here on toxicological applications, as neurotoxicity is one of the major reasons for drug failure (Cook et al. 2014).”
BackgroundProfhEX: AI-based platform for small molecules liability profiling
Lunghini, F., Fava, A., Pisapia, V., Sacco, F. M., Iaconis, D., & Beccari, A. R. (2023) · Journal of Cheminformatics · doi:10.1186/s13321-023-00728-6 · Cited by 19
“[10].”
BackgroundLeveraging pleiotropy for the improved treatment of psychiatric disorders
Woodward, D. J., Thorp, J. G., Middeldorp, C. M., Akóṣílè, W., Derks, E. M., & Gerring, Z. F. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02771-7 · Cited by 15
Eigenmann, M. J., Frances, N., Hoffmann, G., Lavé, T., & Walz, A. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0076 · Cited by 16
“Knowledge about the active drug at the target site is crucial to optimize compound selection (41, 42).”
BackgroundMethodGenomic basis of delayed reward discounting
Gray, J. C., Sanchez‐Roige, S., de Wit, H., MacKillop, J., & Palmer, A. A. (2019) · Behavioural Processes · doi:10.1016/j.beproc.2019.03.006 · Cited by 18
Nielsen, R. B., Kahnt, A., Dillen, L., Wuyts, K., Snoeys, J., Nielsen, U. G., Holm, R., & Nielsen, C. U. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118696 · Cited by 16
Subramanian, V., Ratkova, E. L., Palmer, D. S., Engkvist, O., Fedorov, M. V., & Llinàs, A. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00065 · Cited by 17
“Pulling the Plug:” Time Allocation between Drug Discovery and Development Projects
Subramanian, A. M., Lévesque, M., & van de Vrande, V. (2020) · Production and Operations Management · doi:10.1111/poms.13255 · Cited by 19
“For instance, a thorough analysis of AstraZeneca’s R&D strategy in search of improving R&D productivity in 2011, revealed that although AstraZeneca’s success rates in Phase I were at par with industry benchmarks, the success rates for Phases II and III were significantly lower (Cook et al. 2014).”
BackgroundBarber, J., Sikakana, P., Sadler, C., Baud, D., Valentin, J., & Roberts, R. A. (2020) · Toxicology Research · doi:10.1093/toxres/tfaa106 · Cited by 16
Retout, S., Gieschke, R., Serafin, D., Weber, C., Frey, N., & Hofmann, C. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2535 · Cited by 17
John, L., Mahanta, H. J., Soujanya, Y., & Sastry, G. N. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.106494 · Cited by 17
Novel Insights in Drug Metabolism by MS Imaging
Sugihara, Y., Watanabe, K., & Végvári, Á. (2016) · Bioanalysis · doi:10.4155/bio-2015-0020 · Cited by 16
Studying human disease using human neurons
Ahfeldt, T., Litterman, N. K., & Rubin, L. L. (2016) · Brain Research · doi:10.1016/j.brainres.2016.03.051 · Cited by 18
Ojima, A., & Miyamoto, N. (2018) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.17-00213-3 · Cited by 16
Metadata
- Authors
- Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Pangalos, Menelas N.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-05-16
- Volume
- 13
- Issue
- 6
- Pages
- 419-431
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1967105697
- Cited by
- 1,344
- References
- 75
- Citations by year
- 2026: 90 · 2025: 92 · 2024: 104 · 2023: 110 · 2022: 99 · 2021: 123 · 2020: 118 · 2019: 125 · 2018: 131 · 2017: 115 · 2016: 124 · 2015: 92 · 2014: 20
- FWCI
- 33.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Keywords
- AstraZeneca, drug development pipeline, small molecule drug development, R&D productivity, project success factors, target selection, patient selection, tissue selection, drug safety, business potential, organizational culture, pharmaceutical industry
- MeSH terms
- Animals, Clinical Trials as Topic, Decision Making, Organizational, Drug Industry, Drug Evaluation, Preclinical, Humans, Research Support as Topic, Technology, Pharmaceutical, Drug Design, Organizational Culture, Drugs, Investigational, Models, Organizational, Efficiency, Organizational, Biomedical Research, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.